Inoviq Ltd (ASX: IIQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Inoviq Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $59.67 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 111.53 million
Earnings per share -0.071
Dividend per share N/A
Year To Date Return -18.80%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Inoviq Ltd (ASX: IIQ)
    Latest News

    three excited doctors with hands in the air
    Healthcare Shares

    Here's why the BARD1 (ASX:BD1) share price is crushing it today

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is flying higher today after the company presented data for its…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Why the BARD1 (ASX:BD1) share price is on the rise today

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a postiive update from the company. We…

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Healthcare Shares

    Why is the BARD1 (ASX:BD1) share price jumping today?

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is rising significantly today, adding to strong yearly gains, after the company released…

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    Why the BARD1 (ASX:BD1) share price shot up 10% today

    The BARD1 (ASX: BD1) share price is up today after the company signed an agreement that will help in type…

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Share Market News

    The BARD1 (ASX:BD1) share price eyes record highs after positive research results

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is eyeing a new record high today after positive results from…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the BARD1 (ASX:BD1) share price is climbing 6% today

    The BARD1 Life Sciences Ltd (ASX: BD1) share price is climbing today following a favourable outcome for the company's hTERT…

    Read more »

    A man stands with arms crossed in front of a giant shadow of a body builder representing ASX small-cap stocks.
    Share Market News

    These small cap ASX shares surged more than 100% in February

    From a new BNPL agreement to cancer detection, these 3 small cap ASX shares made game changing announcements in February.

    Read more »

    falling healthcare asx share price Mesoblast capital raising
    ⏸️ ASX Shares

    BARD1 (ASX:BD1) share price plummets 15% on legal proceedings

    The BARD1 (ASX: BD1) share price took a major hit today after the company announced legal proceedings are being brought…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the BARD1 Life Sciences (ASX:BD1) share price is rocketing another 54% today

    The BARD1 Life Sciences (ASX:BD1) share price is rocketing again today, up 54% so far. We look at the company's…

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%?

    The BARD1 Life Sciences share price is up an eye-popping 78% in early afternoon trading. We look at what's driving…

    Read more »

    IIQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Inoviq Ltd

    INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. Its activities include research and development of non-invasive diagnostic tests for early detection of cancer, based on certain proprietary intellectual property. The company was founded on June 30, 1983 and is headquartered in Subiaco, Australia.

    IIQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 Dec 2024 $0.54 $-0.01 -1.85% 44,030 $0.53 $0.54 $0.53
    23 Dec 2024 $0.54 $0.02 3.85% 68,806 $0.52 $0.54 $0.52
    20 Dec 2024 $0.52 $-0.01 -1.90% 117,563 $0.54 $0.54 $0.52
    19 Dec 2024 $0.53 $-0.01 -1.87% 72,542 $0.54 $0.54 $0.52
    18 Dec 2024 $0.54 $0.00 0.00% 73,119 $0.54 $0.54 $0.54
    17 Dec 2024 $0.54 $-0.01 -1.83% 42,716 $0.55 $0.55 $0.54
    16 Dec 2024 $0.55 $0.02 3.81% 542,462 $0.54 $0.58 $0.54
    13 Dec 2024 $0.53 $-0.01 -1.89% 85,994 $0.54 $0.54 $0.53
    12 Dec 2024 $0.53 $0.01 1.90% 164,943 $0.53 $0.55 $0.53
    11 Dec 2024 $0.53 $-0.01 -1.87% 103,918 $0.54 $0.54 $0.52
    10 Dec 2024 $0.54 $-0.01 -1.85% 182,586 $0.55 $0.55 $0.51
    09 Dec 2024 $0.54 $-0.02 -3.54% 291,104 $0.57 $0.58 $0.54
    06 Dec 2024 $0.57 $0.05 9.71% 782,926 $0.54 $0.57 $0.53
    05 Dec 2024 $0.52 $0.02 4.00% 712,789 $0.51 $0.56 $0.51
    04 Dec 2024 $0.50 $-0.02 -3.88% 118,876 $0.53 $0.53 $0.50
    03 Dec 2024 $0.52 $0.05 10.75% 689,864 $0.51 $0.54 $0.50
    02 Dec 2024 $0.47 $0.01 2.17% 31,540 $0.46 $0.47 $0.45
    29 Nov 2024 $0.46 $0.04 9.41% 99,269 $0.45 $0.46 $0.45
    28 Nov 2024 $0.43 $-0.02 -4.55% 44,071 $0.44 $0.44 $0.42
    27 Nov 2024 $0.44 $0.02 4.71% 41,196 $0.42 $0.44 $0.42
    26 Nov 2024 $0.43 $-0.02 -4.55% 140,758 $0.44 $0.44 $0.43

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    29 Nov 2024 Philip (Phil) Powell Issued 250,000 $115,000
    Issue of options.
    29 Nov 2024 Geoffrey Cumming Issued 250,000 $115,000
    Issue of options.
    29 Nov 2024 Robert (Max) Johnston Issued 250,000 $115,000
    Issue of options.
    29 Nov 2024 Mary Harney Issued 250,000 $115,000
    Issue of options.
    30 Sep 2024 Robert (Max) Johnston Expiry 250,000 $125,000
    Options expired.
    30 Sep 2024 Philip (Phil) Powell Expiry 250,000 $125,000
    Options expired.
    30 Sep 2024 Geoffrey Cumming Expiry 250,000 $125,000
    Options expired.
    28 Aug 2024 Geoffrey Cumming Issued 60,000 $30,000
    Placement.
    28 Aug 2024 Geoffrey Cumming Issued 30,000 $17,100
    Placement. As per announcement on 28-08-2024
    28 Aug 2024 David Williams Issued 90,000 $51,300
    Placement.
    28 Aug 2024 David Williams Issued 180,000 $90,000
    Placement.
    28 Aug 2024 Philip (Phil) Powell Issued 60,000 $30,000
    Placement.
    28 Aug 2024 Philip (Phil) Powell Issued 30,000 $17,100
    Placement. As per announcement on 28-08-2024
    28 Aug 2024 Robert (Max) Johnston Issued 200,000 $100,000
    Placement.
    28 Aug 2024 Robert (Max) Johnston Issued 100,000 $57,000
    Placement. As per announcement on 28-08-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David Williams Non-Executive ChairmanNon-Executive Director Nov 2023
    Mr Williams is an experienced Director and investment banker with a record in business development as well as in mergers and acquisitions and capital raising. He has experience advising ASX-listed companies in the food, medical device and pharmaceutical sectors. Mr Williams is currently Managing Director of corporate advisory firm Kidder Williams.
    Mr Philip (Phil) John Powell Non-Executive Director Jun 2019
    Mr Powell has experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other corporate finance assignments across a range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell is the Chair of the Risk Committee.
    Mr Geoffrey A. Cumming Non-Executive Director Jul 2020
    Mr Cumming has held roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Dr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the growing and profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Dr Cumming was in designing and securing funding arrangements through a range of capital raising initiatives, including government grants, partnering and co-development deals. He was previously Chairman of Sienna Cancer Diagnostics Ltd. Dr Cumming is a member of the Risk Committee.
    Mr Robert (Max) Maxwell Johnston Non-Executive Director Jun 2019
    Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston's career also included roles with Diageo and Unilever in Australia, Africa, and Europe. Mr Johnston has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). Mr Johnston has had overseas experience during his career in leading businesses in Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is a member of the Company's Risk Committee.
    Ms Mary Harney Non-Executive Director Oct 2024
    Ms Harney is a Non-Executive Director and Chief Executive and brings a understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation. Ms Harney is the current Chair of Microbio Pty Ltd. She was previously the Chair of Race Oncology (ASX: RAC), a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care.
    Dr Leearne Hinch Chief Executive Officer Nov 2016
    -
    Mr Mark Edwards Chief Financial OfficerCompany Secretary Nov 2022
    -
    Leearne Hinch Chief Executive Officer
    -
    Mark Edwards Chief Financial OfficerCompany Secretary
    -
    Gregory Rice Chief Scientific Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    The Trust Company Australia Limited <Mof A/C> 6,487,000 5.86%
    Fresh Start Australia Pty Ltd 4,000,000 3.61%
    Dr Irmgard Irminger-Finger 3,380,000 3.05%
    The Trust Company (Australia) Limited <Mbf A/C> 3,139,333 2.83%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 2,676,924 2.42%
    Moggs Creek Pty Ltd <Moggs Creek Super A/C> 2,389,747 2.16%
    Citicorp Nominees Pty Limited 2,056,600 1.86%
    Lesamourai Pty Ltd 2,000,000 1.81%
    J P Morgan Nominees Australia Pty Limited 1,667,697 1.51%
    Mr Peter William Rogers and Ms Alida Johanna Clark <R&C Super Fund A/C> 1,304,436 1.18%
    Supergun Pty Ltd <Bricklanding Super Fund A/C> 1,160,000 1.05%
    Trovex Pty Ltd 1,090,000 0.98%
    Mr Nathan Ryan Wagner 1,010,562 0.91%
    Mr Adam Garrigan 1,000,000 0.90%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 997,265 0.90%
    Mr Neil Donal Delroy <The Ndd Investment A/C> 956,000 0.86%
    Traoj Pty Ltd <Traoj A/C> 952,933 0.86%
    David Neate 902,257 0.81%
    B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> 660,000 0.60%
    UBS nominees Pty Ltd 600,000 0.54%

    Profile

    since

    Note